GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Galderma Group AG (OTCPK:GALDY) » Definitions » Other Net Income (Loss)

GALDY (Galderma Group AG) Other Net Income (Loss) : $0 Mil (TTM As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Galderma Group AG Other Net Income (Loss)?

Galderma Group AG's Other Net Income (Loss) for the six months ended in Dec. 2024 was $0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2024 was $0 Mil.

Galderma Group AG Other Net Income (Loss) Historical Data

The historical data trend for Galderma Group AG's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galderma Group AG Other Net Income (Loss) Chart

Galderma Group AG Annual Data
Trend Dec23 Dec24
Other Net Income (Loss)
- -

Galderma Group AG Semi-Annual Data
Jun23 Dec23 Jun24 Dec24
Other Net Income (Loss) - - - -

Galderma Group AG Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galderma Group AG Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Galderma Group AG's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Galderma Group AG Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Galderma Group AG (OTCPK:GALDY) » Definitions » Other Net Income (Loss)
Comparable Companies
XSWX:SDZ XSWX:SFZN XSWX:PPGN XSWX:CURN ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN HKSE:03692 NSE:DIVISLAB XTAE:TEVA ITCI SZSE:000538 UTHR BOM:500087 TSE:4507 SHSE:688506 NSE:TORNTPHARM BOM:543904
Traded in Other Exchanges
GDERF:USA GALDz:UK PY30:Germany GALD:Switzerland
Address
Zahlerweg 10, Zug, CHE, 6300
Website
https://www.galderma.com
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a standalone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 45% of net sales from the US and employs around 6,600 people.